Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for moderate to severe chronic hand eczema refractory to potent topical corticosteroids
2018-002830-19Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hand dermatitis (CHE) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Percent change in mTLSS at week 16. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on 2018-002830-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002830-19.